ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2176 • 2017 ACR/ARHP Annual Meeting

    Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity

    Tereza Lennerova1,2, Lucia Vernerova1, Martin Klein1, Veronika Hruskova1,3, Lucie Andres Cerezo1, Barbora Sumova1,2, Michal Tomcik1,2, Sabina Oreska1,2, Herman F Mann1,2, Josef Zamecnik4, Karel Pavelka1,2, Jiri Vencovsky1,2 and Ladislav Senolt1,2, 1Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Clusterin (also known as apolipoprotein J) is a molecular chaperone that participates in a number of biological processes, such as inflammation and apoptosis. Recent…
  • Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting

    Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal

    Liam O'Neil1, Victor Spicer2, Carol A Hitchon2, Juergen Rech3, Axel J. Hueber4, John Wilkins2, Hani El-Gabalawy1 and Georg Schett3, 1Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 4Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…
  • Abstract Number: 78 • 2017 ACR/ARHP Annual Meeting

    IL-37 Is Associated with Increased Atherogenesis in Patients with Rheumatoid Arthritis

    Barbora Sumova1,2, Tereza Lennerova1,2, Lucie Andres Cerezo1, Hana Hulejova1, Romana Jandova1, Karel Pavelka1,2, Jiri Vencovsky1,2 and Ladislav Senolt1,2, 1Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin-37 (IL-37) is one of few anti-inflammatory cytokines belonging to the IL-1 cytokine family. It is mainly produced by immune cells of innate immunity…
  • Abstract Number: 674 • 2017 ACR/ARHP Annual Meeting

    Identification of IRAK4-Dependent Gene Signature As a Biomarker Candidate for IRAK4 Small-Molecule Inhibitor in Systemic Lupus Erythematosus

    A. Francesca Setiadi1, Kate Senger1, Jason Hackney2, Neta Zuckerman1, Swathi Sujatha-Bhaskar1, George Francis1, Marian Bryan1, Hans Brightbill1, Ali A. Zarrin1 and Michael J. Townsend1, 1Genentech, South San Francisco, CA, 2Bioinformatics and Computational Biology, Genentech, South San Francisco, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease. Interleukin-1 receptor-associated kinase 4 (IRAK4) activity is predicted to affect multiple pathogenic pathways in SLE1. We…
  • Abstract Number: 940 • 2017 ACR/ARHP Annual Meeting

    IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment

    Emily Shuldiner1, Victoria Arthur1, Anne Hinks2, Patricia Woo3, Wendy Thomson2, Elaine F. Remmers4 and Michael J. Ombrello1, 1Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, 2Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 3University College London, London, United Kingdom, 4Genetics and Genomics Branch, NIH, NIAMS, Bethesda, MD

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses…
  • Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting

    Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study

    Shinya Kawashiri1,2,3, Ayako Nishino3,4, Nobutaka Eiraku3, Tamami Yoshitama3, Naoki Matsuoka3, Toshiyuki Aramaki3, Yukitaka Ueki3, Akitomo Okada3, Hiroaki Hamada3, Shuji Nagano3, Keita Fujikawa3 and Atsushi Kawakami1,3, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Departments of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, 4Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…
  • Abstract Number: 2198 • 2017 ACR/ARHP Annual Meeting

    Combinatorial Peripheral Blood Inflammatory and MRI-Based Biomarkers Predict Radiographic Joint Space Narrowing in Knee OA

    Svetlana Krasnokutsky Samuels1, Hua Zhou2, Mukundan Attur1, Jonathan Samuels1, Gregory Chang3, Jenny Bencardino4, Sisi Ma2, Leon Rybak3 and Steven B. Abramson5, 1Rheumatology, NYU Langone Medical Center, New York, NY, 2Bioinformatics, New York University, New York, NY, 3Department of Radiology, NYU Langone Medical Center, New York, NY, 4Radiology, NYU Langone Medical Center, New York, NY, 5Dept of Medicine, NYU Langone Medical Center, New York, NY

    Background/Purpose: Inflammation contributes to OA disease pathogenesis. Subsets of knee OA patients with peripheral blood leukocyte (PBL) detected inflammatory gene expression profiles exhibit more rapid…
  • Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting

    Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time

    Paul Studenic1, Stephan Blüml1, Holger Bang2, Daniela Sieghart1, Daniel Aletaha1, Helmuth Haslacher3, Josef S. Smolen1,4 and Günter Steiner1, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Medical University Vienna, Department of Laboratory Medicine, Vienna, Austria, 4Department of Internal Medicine, Hietzing Hospital, Vienna, Austria

    Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…
  • Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting

    Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients

    Jeffrey R. Curtis1, Kerri Ford2, Lang Chen3, Huifeng Yun3 and Fenglong Xie4, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2Crescendo Bioscience Inc., South San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
  • Abstract Number: 675 • 2017 ACR/ARHP Annual Meeting

    Tissue-Based Biomarkers in Cutaneous Lupus Erythematosus: Type I IFN Responsive Protein Mxa and a Marker for Lymphocytic Inflammation (CD45) Correlate with CLASI Cross-Sectionally and Longitudinally

    Taylor L. Reynolds1, Carrie Wager1, Stefan Hamann1, Xueli Zhang1, Galina Marsh1, Cristina Musselli1, Nathalie Franchimont1, Agnes Gardet1, Robert Dunstan2, Dania Rabah1 and Victoria P Werth3, 1Biogen, Cambridge, MA, 2Abbvie, Worcester, MA, 3University of Pennsylvania and the VA Medical Center, Philadelphia, PA

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is the cutaneous manifestation of SLE, affecting 85% of patients1. CLE is subdivided into acute, subacute and chronic/discoid forms. Discoid…
  • Abstract Number: 969 • 2017 ACR/ARHP Annual Meeting

    Modulation of Cartilage Degradation Biomarkers Reflect the Activation and Inhibition of Pro-Inflammatory Cytokine Signaling in an Ex Vivo Model of Bovine Cartilage

    Cecilie F. Kjelgaard-Petersen1,2, Neha Sharma1,3, Ashref Kayed4,5, Britt Christensen1, Morten Karsdal6, Anne-C. Bay-Jensen7 and Christian S. Thudium1, 1Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Bioengineering, Technical University of Denmark, Kgs. Lyngby, Denmark, 3Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 4Research and Biomarkers, Nordic Bioscience, Herlev, Denmark, 5Biomolecular Sciences, University of Copenhagen, Copenhagen, Denmark, 6Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, 7Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Several inflammatory cytokines and intracellular signaling pathways have been targeted in drug development with varying clinical results. Improved understanding of the intracellular signaling’s modulation…
  • Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting

    Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission

    Arata Nakajima1, Masato Sonobe1, Shinji Taniguchi1 and Koichi Nakagawa2, 1Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, 2Toho University Sakura Medical Center, Sakura-city, Chiba, Japan

    Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
  • Abstract Number: 2207 • 2017 ACR/ARHP Annual Meeting

    Urine CTX-II, CTX-I, Osteocalcin, and Radiographic Severity of Multiple OA Knee Joints: Does CTX-II Originate from Bone or Cartilage?

    Asger R. Bihlet1, Inger Byrjalsen2, Anne C. Bay-Jensen3, Jeppe Andersen4, Claus Christiansen1, Bente J. Riis1 and Morten Asser Karsdal3, 1Nordic Bioscience, Clinical Development, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3Rheumatology, Nordic Bioscience, Herlev, Denmark, 4Clinical Development, Nordic Bioscience, Herlev, Denmark

    Background/Purpose: Excessive cartilage degradation is a known characteristic of osteoarthritis (OA), and several methods of quantification of cartilage degradation exist. Biomarkers such as urinary C-telopeptide…
  • Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting

    CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis

    Vikas Gupta1, Shobhita Katiyar2, Ankita Singh2, Ramnath Misra1 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…
  • Abstract Number: 138 • 2017 ACR/ARHP Annual Meeting

    Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity

    Fenglong Xie1, Lang Chen2, Huifeng Yun2 and Jeffrey R. Curtis3, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The ACC/AHA recommends preventive strategies for patients with a high predicted risk of atherosclerotic cardiovascular disease (CVD). RA patients are at higher risk for…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology